Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride

Quality of Life Research

Volumn 25, Issue 5, 2016, Pages 1199-1207

  Chirila, Costel ^a   Zheng, Qingyao ^a   Davenport, Eric ^a   Kaschinski, Dagmar ^b   Pfarr, Egon ^b   Hach, Thomas ^b   Palencia, Roberto ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Diabetes Treatment Satisfaction Questionnaire; Empagliflozin; Glimepiride; Type 2 diabetes mellitus

Indexed keywords

EMPAGLIFLOZIN; GLIMEPIRIDE; METFORMIN; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES TREATMENT SATISFACTION QUESTIONNAIRE; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; EXPLORATORY RESEARCH; FEMALE; GLYCEMIC CONTROL; HOME; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; CHEMICALLY INDUCED; CLINICAL PROTOCOL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MIDDLE AGED; PSYCHOLOGY; QUALITY OF LIFE; SATISFACTION; TREATMENT OUTCOME;

ADULT; BENZHYDRYL COMPOUNDS; CLINICAL PROTOCOLS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PERSONAL SATISFACTION; QUALITY OF LIFE; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84944710820     PISSN: 09629343     EISSN: 15732649     Source Type: Journal    
DOI: 10.1007/s11136-015-1140-2     Document Type: Article

References (19)

1. International Diabetes Federation. (2013). IDF diabetes atlas (6th ed.). http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf. Accessed 26 Nov 2014.
2. Pyerot, M., & Rubin, R. R. (2009). How does treatment satisfaction work? Modeling determinants of treatment satisfaction and care. Diabetes Care,32, 1411–1417.
3. Bradley, C., & Gamsu, D. S. (1994). Guidelines for encouraging psychological well-being: Report of a working group of the World Health Organization Regional Office for Europe and International Diabetes Federation European Region St Vincent Declaration Action Programme for Diabetes. Diabetic Medicine,11, 510–516.
4. Bradley, C., & Gilbride, C. J. B. (2008). Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: The role of once-daily insulin glargine. Diabetes, Obesity and Metabolism Journal,10(suppl 2), 50–65.
5. Blonde, L. (2010). Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus. The American Journal of Medicine,123, S12–S18.
6. Wright, E. M. (2001). Renal Na(+)-glucose cotransporters. American Journal of Physiology-Renal Physiology,280(1), F10–F18.
7. Wright, E. M., & Turk, E. (2004). The sodium/glucose cotransport family SLC5. Pflügers Archiv: European Journal of Physiology,447(5), 510–518.
8. Ferrannini, E., Seman, L., Seewaldt-Becker, E., Hantel, S., Pinnetti, S., & Woerle, H. J. (2010). The potent and highly selective sodium glucose cotransporter-2 (SGLT-2) inhibitor BI 10773 is safe and efficacious as monotherapy in patients with type 2 diabetes mellitus. Diabetologia,53, S531.
9. Rosenstock, J., Seman, L. J., Jelaska, A., Hantel, S., Pinnetti, S., Hach, T., et al. (2013). Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes, Obesity and Metabolism,15(12), 1154–1160.
10. Häring, H. U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Woerle, H. J., et al. (2013). Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week randomized, double-blind, placebo-controlled trial. Diabetes Care,36, 3396–3404.
11. Ridderstråle, M., Andersen, K. R., Zeller, C., Kim, G., Woerle, H. J., Broedl, U. C., & EMPA-REG H2H-SU trial investigators. (2014). Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. The Lancet Diabetes & Endocrinology,2(9), 691–700.
12. Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., et al. (2015). Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care,38, 140–149.
13. National Institute for Health and Care Excellence. (2014). Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 87. http://www.nice.org.uk/guidance/cg87/resources/guidance-type-2-diabetes-pdf. Accessed 23 June 2015.
14. Bradley, C., & Lewis, K. S. (1990). Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabetic Medicine,7, 445–451.
15. Bradley, C. (1994). Diabetes Treatment Satisfaction Questionnaire: (DTSQ). In C. Bradley (Ed.), Handbook of psychology and diabetes: A guide to psychological measurement in diabetes research and practice (pp. 111–132). Chur: Harwood Academic Publishers.
16. Gelhorn, H. L., Stringer, S. M., Brooks, A., Thompson, C., Monz, B. U., Boye, K. S., et al. (2013). Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK. Diabetes, Obesity and Metabolism,15(9), 802–809.
17. Howorka, K., Pumprla, J., Schlusche, C., Wagner-Nosiska, D., Schabmann, A., & Bradley, C. (2000). Dealing with ceiling baseline treatment satisfaction level in patients with diabetes under flexible, functional insulin treatment: assessment of improvements in treatment satisfaction with a new insulin analogue. Quality of Life Research,9, 915–930.
18. Bradley, C., Plowright, R., Stewart, J., Valentine, J., & Witthaus, E. (2007). The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ. Health and Quality of Life Outcomes,5, 57.
19. Bradley, C. (2006). Feedback on the FDA’s February 2006 draft guidance on patient-reported outcome (PRO) measures from a developer of PRO measures. Health and Quality of Life Outcomes,4, 78.